In NSCLC, molecular analyses focus on actionable biomarkers associated with regulatory agency-approved therapies, including activating mutations of EGFR and BRAF and chromosomal rearrangements resulting in ALK, ROS1, and NTRK1–3 gene fusions. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.